explore -WSS

explore

author：Wikipedia 2025-09-27 16:47:59 - browse：68732

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： A $475,000 price tag for a new cancer drug: crazy or meh?

WSS

Ebola public health emergency is over, WHO declares

Woodcock on FDA’s accelerated approval and her next chapter

'Reaching a detente': STAT's Helen Branswell on covering Covid

Seattle police shoot person suspected in downtown stabbing

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

FDA drug safety: Singulair case shows systemic surveillance flaws

hotspot

explore

entertainment

How to save PrEP access — and even expand it

Biden administration opens offers in Medicare drug price negotiations

Bright Health sells Medicare Advantage business to Molina

Apple Vision Pro: A first look at health apps on the new VR headset

Jerome Adams on the need for new antivirals for Covid

Congressmen charge Covid hearing ‘could have been an email’

Sports medicine is finally prioritizing gender equality

Apple Vision Pro: A first look at health apps on the new VR headset

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

India sets sights on home

focus

Lindsay Lohan welcomes 1st child with husband Bader Shammas

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

ARCH Venture Partners is raising $3 billion for a life sciences fund

Vertex non

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

A $475,000 price tag for a new cancer drug: crazy or meh?

focus

knowledge

focus

focus